Malignant lymphomas 1969–2001 in a combined population based cohort of 47 679 Swedish patients with inflammatory bowel disease
| Ulcerative colitis | Crohn’s disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| O | E | SIR (95% CI) | RR | p Value | O | E | SIR (95% CI) | RR | p Value | |
| First year of follow up excluded. | ||||||||||
| Observed (O) and expected (E) number of malignant lymphomas, standardised incidence ratio (SIR) with 95% confidence intervals (95% CI), and multivariate relative risks (RR) from models including all parameters in table (“ref” denotes reference category). | ||||||||||
| p values refer to type 3 tests. | ||||||||||
| Overall | 87 | 84 | 1.0 (0.8–1.3) | – | – | 65 | 50 | 1.3 (1.0–1.6) | – | – |
| Sex | ||||||||||
| Male | 50 | 53 | 0.9 (0.7–1.2) | 1 (ref) | 0.29 | 42 | 29 | 1.5 (1.1–2.0) | 1 (ref.) | 0.20 |
| Female | 37 | 31 | 1.2 (0.8–1.6) | 1.3 (0.8–1.9) | 23 | 22 | 1.1 (0.7–1.6) | 0.7 (0.4–1.2) | ||
| Cohort of origin | ||||||||||
| Any regional cohort | 19 | 23 | 0.8 (0.5–1.3) | 0.8 (0.5–1.5) | 0.56 | 18 | 14 | 1.3 (0.8–2.0) | 1.0 (0.6–2.0) | 0.76 |
| Inpatient register only | 68 | 62 | 1.1 (0.9–1.4) | 1 (ref) | 47 | 36 | 1.3 (1.0–1.7) | 1 (ref.) | ||
| Calendar period at follow up | ||||||||||
| –1979 | 4 | 5.8 | 0.7 (0.2–1.8) | 1 (ref) | 0.63 | 5 | 3.1 | 1.6 (0.5–3.8) | 1 (ref.) | 0.34 |
| 1980–1989 | 24 | 22 | 1.1 (0.7–1.6) | 1.6 (0.5–4.5) | 11 | 12 | 0.9 (0.5–1.6) | 0.6 (0.2–1.8) | ||
| 1990–2001 | 59 | 57 | 1.0 (0.8–1.3) | 1.6 (0.5–4.5) | 49 | 35 | 1.4 (1.0–1.8) | 1.0 (0.4–2.6) | ||
| Time of follow up (y) | ||||||||||
| 1–5 | 36 | 26 | 1.4 (1.0–1.9) | 1.4 (0.8–2.3) | 0.09 | 23 | 14 | 1.6 (1.0–2.4) | 1.1 (0.5–2.2) | 0.42 |
| 6–10 | 14 | 19 | 0.7 (0.4–1.2) | 0.7 (0.4–1.4) | 12 | 12 | 1.0 (0.5–1.8) | 1.0 (0.4–1.6) | ||
| ⩾11 | 37 | 39 | 1.0 (0.7–1.3) | 1 (ref) | 30 | 25 | 1.2 (0.8–1.8) | 1 (ref.) | ||